Dr. Schuster on GO29781 Trial With Mosunetuzumab in NHL

Stephen J. Schuster, MD
Published: Thursday, Mar 26, 2020



Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).

New drugs for patients with B-cell lymphomas, including large B-cell lymphomas (LBCL), aggressive NHLs, and indolent NHLs, continues to be an unmet need, says Schuster.

Mosunetuzumab is a new bispecific antibody that binds to CD20 on B cells and CD3 on T cells. The agent is designed to eradicate B cells with a patient’s T cells, explains Schuster. GO29781 enrolled patients with LBCL—mainly diffuse large B-cell lymphoma, but also follicular lymphoma and mantle cell lymphoma. The study also accrued patients with more indolent lymphomas, adds Schuster.

In the study, investigators evaluated the tolerability, toxicity, maximum-tolerated dose, and efficacy of the drug. Notably, objective responses were observed in both aggressive and indolent lymphomas across all dose levels. Additionally, patients who did not respond to CAR T-cell therapy achieved a similar response rate to those with aggressive lymphomas who had not received prior CAR T-cell therapy, concludes Schuster.
SELECTED
LANGUAGE


Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).

New drugs for patients with B-cell lymphomas, including large B-cell lymphomas (LBCL), aggressive NHLs, and indolent NHLs, continues to be an unmet need, says Schuster.

Mosunetuzumab is a new bispecific antibody that binds to CD20 on B cells and CD3 on T cells. The agent is designed to eradicate B cells with a patient’s T cells, explains Schuster. GO29781 enrolled patients with LBCL—mainly diffuse large B-cell lymphoma, but also follicular lymphoma and mantle cell lymphoma. The study also accrued patients with more indolent lymphomas, adds Schuster.

In the study, investigators evaluated the tolerability, toxicity, maximum-tolerated dose, and efficacy of the drug. Notably, objective responses were observed in both aggressive and indolent lymphomas across all dose levels. Additionally, patients who did not respond to CAR T-cell therapy achieved a similar response rate to those with aggressive lymphomas who had not received prior CAR T-cell therapy, concludes Schuster.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x